Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13

IF 2.9 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of Medical Economics Pub Date : 2024-04-05 DOI:10.1080/13696998.2024.2339638

Mark H. Rozenbaum, Liping Huang, Alejandro Cane, Adriano Arguedas, Ruth Chapman, Desmond Dillon-Murphy, Maria Tort, Vincenza Snow, Erica Chilson, Raymond Farkouh

引用次数: 0

Abstract

The US Food and Drug Administration approved the 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease. In the context of routine PCV20 vaccination, we evaluated the cost...

查看原文本刊更多论文

美国儿童接种 20 价肺炎球菌结合疫苗的成本效益及其对感染和相关抗菌药耐药性的影响

美国食品和药物管理局批准使用 20 价肺炎球菌结合疫苗 (PCV20) 预防肺炎球菌疾病。在 PCV20 疫苗常规接种的背景下，我们评估了接种该疫苗的成本...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Economics HEALTH CARE SCIENCES & SERVICES-MEDICINE, GENERAL & INTERNAL

CiteScore

4.50

自引率

4.20%

发文量

122

期刊介绍： Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication. Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience